Weekly Analysts’ Ratings Updates for VolitionRx (VNRX)

VolitionRx (NYSE: VNRX) recently received a number of ratings updates from brokerages and research firms:

• 1/23/2025 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 1/15/2025 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 1/8/2025 – VolitionRx had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
• 1/7/2025 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 12/30/2024 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 12/22/2024 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 12/14/2024 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 12/10/2024 – VolitionRx had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
• 12/6/2024 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 11/28/2024 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.

VolitionRx Stock Performance

Shares of NYSE VNRX traded up $0.00 during trading on Friday, hitting $0.63. The company had a trading volume of 157,211 shares, compared to its average volume of 108,033. The stock has a 50 day simple moving average of $0.64 and a 200 day simple moving average of $0.66. The firm has a market capitalization of $58.57 million, a P/E ratio of -1.76 and a beta of 1.20. VolitionRx Limited has a 12 month low of $0.43 and a 12 month high of $1.23.

Insider Activity at VolitionRx

In related news, CEO Cameron John Reynolds bought 139,811 shares of the business’s stock in a transaction dated Monday, December 9th. The shares were purchased at an average price of $0.57 per share, with a total value of $79,692.27. Following the transaction, the chief executive officer now owns 2,117,404 shares in the company, valued at $1,206,920.28. This trade represents a 7.07 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Guy Archibald Innes purchased 174,764 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was bought at an average price of $0.57 per share, with a total value of $99,615.48. Following the completion of the transaction, the director now owns 617,085 shares of the company’s stock, valued at $351,738.45. The trade was a 39.51 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 358,266 shares of company stock valued at $204,212. 12.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Geode Capital Management LLC raised its position in shares of VolitionRx Limited (NYSE:VNRX) by 15.1% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 730,448 shares of the company’s stock after buying an additional 95,900 shares during the quarter. Geode Capital Management LLC owned about 0.79% of VolitionRx worth $439,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.